Related Experiment Videos

Ototoxicity of an ototopic preparation--experimental results and clinical facts

A R Halama1, C G Wright, W L Meyerhoff

  • 1Department of Otorhinolaryngology, Head/Neck Surgery, Akademisch Ziekenhuis, Vrije Universiteit Brussel, Belgium.

Acta Oto-Rhino-Laryngologica Belgica
|January 1, 1991
PubMed

Insights

Cortisporin Otic Suspension can cause hearing loss. This study found polymyxin B in the ear drops caused significant cochlear damage in baboons, highlighting the ototoxicity risks.

Area of Science:

  • Ototoxicity research
  • Pharmacology of ear medications
  • Auditory system investigation

Background:

  • Cortisporin Otic Suspension is a common ear drop formulation.
  • Concerns exist regarding the ototoxic potential of topical ear medications.
  • Neomycin and polymyxin B are active ingredients in Cortisporin.

Purpose of the Study:

  • To investigate the ototoxicity of Cortisporin Otic Suspension.
  • To evaluate the individual contributions of neomycin and polymyxin B to cochlear damage.
  • To assess the safety of topical ear drops in clinical settings.

Main Methods:

  • Utilized the baboon (Papio ursinus) as an animal model.
  • Administered Cortisporin Otic Suspension to the ears of baboons.
  • Examined cochlear tissues for hair cell loss and other lesions.
  • Separately tested polymyxin B and neomycin at equivalent concentrations.

Main Results:

  • All baboon cochleas treated with Cortisporin showed inner and outer hair cell loss.
  • The majority of observed lesions were concentrated in the basal turn of the organ of Corti.
  • Polymyxin B demonstrated greater cochlear damage compared to neomycin at the same concentrations.

Conclusions:

  • Cortisporin Otic Suspension exhibits significant ototoxicity.
  • Polymyxin B is a primary contributor to the observed cochlear damage.
  • Clinicians should exercise caution when prescribing topical ear preparations that may access the middle ear.

Related Concept Videos